Skip to content
TrialScanner

NCT07020923

Monthly Dosing of Atacicept in IgAN

Phase 2Active, not recruitingVERALead

Registry record

Lead sponsor
Vera Therapeutics, Inc.
Conditions
IgA Nephropathy (IgAN); Berger Disease
Primary completion
Sep 22, 2026Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT07020923 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

1 change recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT07020923: Monthly Dosing of Atacicept... | TrialScanner